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The weekly ILI morbidity and inﬂuenza positive samples
in selected sites
Conclusion: This active surveillance showed a certain
existence of ILI morbidity and hospitalization especially
among 0-4 age children, but there was no death observed
during this period. In addition there were some cases of ILI
seen while no inﬂuenza was detected. A multiple year study
is necessary to ﬁgure out the disease burden of inﬂuenza and
at the same time further study including etiological study
is also necessary. At the moment, this community based
information is useful to respond current pandemic (H1N1)
2009.
doi:10.1016/j.ijid.2010.02.1676
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Clinical proﬁle and outcome in 100 patients admitted with
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Background: Pandemic Inﬂuenza Virus (AH1N1) has been
identiﬁed as the cause of respiratory infection worldwide,
has been linked to severe respiratory failure requiring fre-
quently ICU admissions
Methods: We describe the clinical and epidemiologic
characteristics of 100 patients(p) hospitalized at these
intensive care units with laboratory conﬁrmed (RT-PCR) or
acute febrile respiratory illness epidemiologically linked.
Results: 60p were conﬁrmed and 40 were epidemiogically
suspected cases. Mean Age: 45 yrs (± 16,8); 84%< 60yrs
Clinical proﬁle: cough (96%), dyspnea (93%), fever(90%),
bronchospasm (51%), headache (41%), myalgias(42%),
obtundness (35%)
Risk Factors: 31p had a body mass index >30; in 13% obe-
sity was the only risk factor. COPD (33%), cardiovascular
disease(19%), diabetes(16%), asthma(14%), pregnancy(10%).
White count cell in 70p was less than 10.000. 76p had less
than 1000 lynphocites, CPK wes elevated in 60p All tested
patients had elevated LDH; in 37/80 p>1000 IU, Most p (82)
showed bilateral interstitial alveolar images.
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iAcute Respiratoty Distress Sindrome was present in 60 p.
nvasive Mechanical Ventilation was instituted in 54 p. Alve-
lar recruitment maneuvers were necessary in 36 p; in 20
f which oxemia improved. When recruitment failed prone
osition was instituted: 7/12p also improved St pneumo-
iae was identiﬁed in 22 p (18 in tracheal aspirates and 4 in
lood cultures). In 84 p Oseltamivir was indicated; average
ose 150mg per day for 7 days. Pts who did not respond to
reatment or in obese the dose was increased to 450mg. Cor-
icosteroid were indicated most due to bronchospasm(61p)
he most important complications were trombosis (7p) and
eptic shock (35p).The most common cause of death (24/28)
as respiratory failure
Conclusion: The vast majority of our patients were
ounger than 60. High frequency of bronchospasm, myal-
ia and obtundness. Obesity and pregnancy, are special risk
actors. Lymphopenia, elevated LDH and CPK represent lab-
ratory ﬁndings. Both lungs are usually compromised.
These patients have high mortality linked to respiratory
efractory failure.
oi:10.1016/j.ijid.2010.02.1677
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nfection in high-risk patients
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Background: The ongoing pandemic of 2009/H1N1
nﬂuenza has increased the awareness of the impact and
npredictable nature of inﬂuenza. This in turn has raised
he interest in the development of additional drugs to treat
he disease when vaccinations fall short. The patient pop-
lation of most concern are those classiﬁed as ‘‘high-risk’’
here inﬂuenza causes substantial morbidity and mortality.
his high-risk group comprises individuals with underly-
ng chronic disease. In this study, efﬁcacy and safety of
ntravenous administration of peramivir were evaluated in
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nﬂuenza patients with one or more high-risk co morbidities.
Methods: The study was a double-blind, multi-center
tudy of intravenous peramivir with dosing over multi-
le days. The study enrolled 42 inﬂuenza patients with
omplications due to one or more qualifying conditions:
iagnosis with poorly controlled diabetes mellitus, a chronic
espiratory disease requiring pharmacotherapy, or current
reatment with any immunosuppressive drug. Peramivir was
dministered at 300mg or 600mg per day, and the dura-
ion was adjusted (up to ﬁve days) on a case-by-case basis,
epending on the patient’s temperature and clinical condi-
ion as determined by the treating physician.
Results: In this study, the median time to alleviation
f symptoms in all 37 evaluable patients treated with
ither 300mg or 600mg peramivir daily was 68.6 hrs (90%
I, 41.5 hrs - 113.4 hrs). The median time for each group
300mg and 600mg) was 114.4 hrs and 42.3 hrs respectively,
hile the time for each group categorized as single-dosed
n = 10) and multipledosed (n = 27) was 92.0 hrs and 64.1 hrs,
espectively. The incidence of pneumonia, which was the
ain complication resulting from inﬂuenza was 8.1% (3/37).
here were no drugrelated SAEs throughout the study.
Conclusion: The results suggest that intravenous
eramivir was effective for treatment of inﬂuenza patients
ith a high-risk for complications co morbidities and
ncreased risk for complications due to inﬂuenza infection.
oi:10.1016/j.ijid.2010.02.1678
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euraminidase sub typing and drug resistance among
nﬂuenza A viruses circulating in western India
. Potdar ∗, M. Dakhave, M. Chadha, A. Mishra
National Institute of Virology, 421001, India
Background: Inﬂuenza viruses are important respira-
ory pathogens in India. Clinical, virological and molecular
urveillance is being carried out under a Multi- site Inﬂuenza
urveillance project (Indian Council of Medical Research-
enters for Diseases Control). National Institute of Virology,
une, India monitors genetic variations and drug suscepti-
ility in circulating inﬂuenza viruses. Most of the inﬂuenza
viruses are amantadine resistance worldwide and hence
euraminidase inhibitors (NAI) oseltamivir or zanamivir are
ecommended for the treatment of infection with inﬂuenza
iruses.
Methods: Neuraminidase sub typing of 42 H1 and 48 H3
iruses from the year 2003 to April 2009 were carried out
y one step diagnostic RT PCR using published primers.
niversal M13 primers forward and reverse were used for
equencing and subtypes of isolates were conﬁrmed by blast
nalysis. 253 bp product of N1 isolates contains established
utation site H274Y leading to oseltamivir resistance .To
heck the mutation sites E119V, I222V, R292K, N294S and -
44-247 for N2 isolates; further 1103 bp N2 gene was ampli-
ed using speciﬁc primers.
Results: NA Subtyping: 90 inﬂuenza A isolates from 2003-pril 2009 circulating in Pune were ampliﬁed. 90 inﬂuenza
isolates were conﬁrmed as 42 N1 and 48 N2 respectively
y sequencing. No unusual combinations were observed
etection of drug resistant sites for N1 and N2 isolates:
c
m
mternational Congress on Infectious Diseases (ICID) Abstracts
1 isolates:253 bp ampliﬁed product of N1 isolates which
ncluded the established mutation site H274Y leading to
seltamivir resistance was analyzed by sequencing. All N1
solates were sensitive to oseltamivir. N2 isolates: To check
he mutation sites for N2 (E119V, I222V, R292K, N294S and
244- 247); further 1103 bp products were ampliﬁed. All 44
2 isolates were sensitive to both the drugs oseltamivir and
anamivir.
Conclusion: All seasonal inﬂuenza A viruses A/H1N1 and
/H3N2 were sensitive to neuraminidase inhibitors. Antivi-
al drugs against inﬂuenza are rarely used in India as a
herapeutic agent. However due to globalization, resistant
iruses could be seeded in Pune from elsewhere.Though no
esistant viruses were detected, continuous surveillance of
nﬂuenza viruses is needed to monitor circulating strains,
nd their drug susceptibility in view of pandemic potential
f inﬂuenza virus.
oi:10.1016/j.ijid.2010.02.1679
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nﬂuenza in the tropics - Epidemiology and burden
. Da Silva ∗, M.H. Kyaw
Novartis Vaccines and Diagnostics, Cambridge, MA, USA
Background: Although inﬂuenza presents a signiﬁcant
urden in the tropics, the belief that this disease primarily
ffects people in temperate climates and developed coun-
ries persists because of peculiar circumstances of disease
pidemiology, other local causes of morbidity and mortality,
nd better surveillance systems in countries in temperate
egions. The public health burden of inﬂuenza is high in the
ropics, particularly in children, yet it has been suggested
hat vaccination programs would not be cost-effective in this
egion because little is known about the true impact of the
isease.
Methods: Systematic literature review of Medline using
earch terms of inﬂuenza, tropical, and epidemiology.
Results: In Medline, 155 manuscripts were published
etween 1969 and 2009. Inﬂuenza in tropical regions has
ained more attention in the medical literature in the
wenty-ﬁrst century; 118 of 155 papers (76%) appeared after
999. Twenty-three studies presented data on laboratory-
onﬁrmed cases of inﬂuenza in tropical regions. Outbreaks
nd epidemics present a signiﬁcant public health bur-
en in tropical regions. For example, in Madagascar in
002, more than 27,000 cases of inﬂuenza and 800 deaths
ccurred within a period of three months despite rapid pub-
ic health intervention. In tropical regions, viral transmission
s usually year-round and commonly has two peaks annu-
lly. Co-circulation of what are considered ‘‘northern’’ or
‘southern’’ strains occurs year-round in tropical regions.
ropical regions, thus, may be the source of new strains
hat are then disseminated to other latitudes. However, the
linical characteristics, impact on healthcare services, and
easonal variation of inﬂuenza in tropical regions are still not
learly understood, based on the current literature. A third
ategory of strain recommendation for inﬂuenza vaccines
ay be needed for tropical regions.
Conclusion: The burden of inﬂuenza in tropical countries
ay be higher than in North America or Europe. More stud-
